Navigation Links
Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C
Date:10/10/2011

ment naive patients with HCV genotype 1 (GT1) in the US.

About ELECTRON

ELECTRON is an exploratory study of PSI-7977 for the treatment of chronic HCV infection. Part 1 of the trial is evaluating 12-week regimens of interferon-free PSI-7977 400mg QD with ribavirin (RBV), and three abbreviated duration peginterferon (Peg-IFN) regimens of 4, 8, or 12 weeks in treatment-naive patients with HCV GT2 or GT3. The primary endpoint of the trial is the safety and tolerability of PSI-7977 400mg QD and RBV for 12 weeks, administered with or without Peg-IFN. On May 11, 2011, Pharmasset announced the completed enrollment of Part 1 of ELECTRON:

  • PSI-7977 400 mg with Peg-IFN and RBV for 12 weeks (GT2/3)
  • PSI-7977 400 mg with RBV for 12 weeks, Peg-IFN weeks 1-8 only (GT2/3)
  • PSI-7977 400 mg with RBV for 12 weeks; Peg-IFN weeks 1-4 only (GT2/3)
  • PSI-7977 400 mg with RBV for 12 weeks (GT2/3)

In Part 2 of ELECTRON, a 5th cohort was added to explore PSI-7977 monotherapy in treatment naive patients with HCV GT2 or GT3:

  • PSI-7977 400 mg monotherapy for 12 weeks (n=10 GT2/3)

Following on the previously reported 100% SVR12 in treatment-naive subjects with HCV GT2/3 (PROTON), a 6th cohort was added to ELECTRON to explore an 8-week duration of PSI-7977Peg-IFN/RBV.  The previously announced 7th cohort in HCV GT1 patients with a prior "null" response to Peg-IFN, has been modified to an interferon-free 12-week regimen of PSI-7977/RBV.

  • PSI-7977 400 mg with Peg-IFN/RBV for 8 weeks (n=10 GT2/3 treatment-naive)
  • PSI-7977 400 mg with RBV for 12 weeks (n=10 GT1 null)

In Part 3 of ELECTRON, two additional IFN-free regimens will be explored in treatment-naive patients with HCV GT1 and in treatment-experienced patients with HCV GT2 or GT3.  

    '/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset to Present at Two Upcoming Conferences
2. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
3. Pharmasset Announces Two-for-One Forward Stock Split
4. Pharmasset to Present at Canaccord Genuity Growth Conference
5. Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
6. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
7. Pharmasset to Present at Two Upcoming Investor Conferences
8. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
9. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
10. Pharmasset to Webcast an Investor Event From the EASL Meeting
11. Pharmasset to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, ... that results from the  IAP310 study have been ... (RAPM), a peer-reviewed journal with broad, multidisciplinary ... trial evaluating the safety and efficacy of Zalviso, ... system (SSTS), for the treatment of post-operative pain ...
(Date:10/22/2014)... , Oct. 22, 2014   Foundation ... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ) ... genomic profiling to biopharmaceutical companies conducting clinical trials in ... the terms of the collaboration, Foundation Medicine will license ... Foundation Medicine,s FoundationOne® assay at the WuXi Genome Center ...
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional medical ... Toronto -based 3D visualization leader ... of Neurological Surgeons Annual Meeting that they have ... brain surgery. The collaboration is the first of ... to improve patient outcomes. NICO,s BrainPath® interventional access ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... 14, 2012 Ingenol mebutate was proven efficacious ... Today, the New England Journal of Medicine (NEJM) ... Phase III clinical trials for ingenol mebutate gel, demonstrating that ... of actinic keratoses (AKs) on the trunk-extremities or face-scalp with ...
... DIEGO, March 14, 2012 Arena Pharmaceuticals, Inc. (NASDAQ: ... the fourth quarter and full year ended December 31, ... the potential to be an important option for physicians ... lose weight and improve their overall cardiometabolic health," said ...
Cached Medicine Technology:New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses 2New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses 3New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses 4New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses 5Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 3Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 4Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 5Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 6Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 7Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 8
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
(Date:10/22/2014)... Dennis Thompson HealthDay ... U.S. health officials on Monday officially tightened guidelines for health ... no skin exposure and use of a respirator at all ... decided to issue the tougher rules after two Dallas nurses ... in the United States, Liberian national Thomas Eric Duncan. Nina ...
(Date:10/20/2014)... October 20, 2014 With a mere ... Charlie Crist made a brief fundraising stop at the ... Thursday. , Fresh from a debate last night with ... the stage for the first seven minutes because Crist ... governor described the incident in one word: "weird." , ...
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 hc1.com ... a secure cloud solution that enables healthcare organizations ... the ultimate healthcare-specific customer relationship management (“CRM”) solution. ... the unique needs of the healthcare industry, the ... for providers and patients by combining healthcare CRM, ...
Breaking Medicine News(10 mins):Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
... on the internet do not contain the ingredients they claim. ... over the internet. These are findings of Dr. Mark Baron, ... see what each contained. The study is published today in ... is clear that consumers are buying products that they think ...
... CAA multi-institutional team headed by Ursula Bellugi, professor and ... Salk Institute for Biological Studies, has been awarded a ... of Child Health and Human Development (NICHD) to link ... basis using Williams syndrome as a model. ...
... Kathleen Doheny HealthDay Reporter , THURSDAY, May ... in Afghanistan or Iraq face a higher risk of ... Researchers from the Uniformed Services University of the Health ... whose parents were on active duty between 2007 and ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... the chest after an road accident has been able to ... take some assisted steps on a treadmill, thanks to electrical ... called epidural spinal cord stimulation -- mimics signals the brain ...
... effect of impairing the patient,s immune system. This can ... especially since bacteria, like Staphylococcus aureus , are ... Central,s open access journal Annals of Clinical Microbiology ... plants against bacterial and fungal infections in the mouths ...
... University of California, Los Angeles (UCLA), the California Institute ... used a stimulating electrode array to assist a paralyzed ... and, over time, to regain voluntary movements of his ... researchers have found, stimulate the spinal cord,s own neural ...
Cached Medicine News:Health News:Buying 'legal highs' from the Internet is a risky business 2Health News:NIH awards Salk Institute $5.5 million grant to study Williams syndrome 2Health News:Kids of Deployed Parents May Face Mental Health Risks 2Health News:Kids of Deployed Parents May Face Mental Health Risks 3Health News:Spinal Stimulation Helps Paralyzed Man Regain Movement 2Health News:Spinal Stimulation Helps Paralyzed Man Regain Movement 3Health News:Spinal Stimulation Helps Paralyzed Man Regain Movement 4Health News:Herbal remedies offer hope as the new antibiotics 2Health News:Caltech research helps paraplegic man stand and move legs voluntarily 2Health News:Caltech research helps paraplegic man stand and move legs voluntarily 3Health News:Caltech research helps paraplegic man stand and move legs voluntarily 4Health News:Caltech research helps paraplegic man stand and move legs voluntarily 5
Pre-Loaded with a Stylet., ,Available Cuffed or Uncuffed, pre-loaded with a stylet to facilitate quick intubations....
... volume tapered, low pressure cuff., ,Sheridan ... today's healthcare professionals., High level of tactile ... allows the tube to soften at body ... gently cupped to minimize trauma during intubation ...
Adult (ICU) Tracheal Tubes with Micro-thin-walled cuffs....
Indications For Usage: ,Microlaryngeal surgery....
Medicine Products: